JP2002531123A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531123A5
JP2002531123A5 JP2000586893A JP2000586893A JP2002531123A5 JP 2002531123 A5 JP2002531123 A5 JP 2002531123A5 JP 2000586893 A JP2000586893 A JP 2000586893A JP 2000586893 A JP2000586893 A JP 2000586893A JP 2002531123 A5 JP2002531123 A5 JP 2002531123A5
Authority
JP
Japan
Prior art keywords
animal
host
antibody
psoriasis
reduced immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000586893A
Other languages
English (en)
Japanese (ja)
Other versions
JP3579355B2 (ja
JP2002531123A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/029123 external-priority patent/WO2000034459A1/en
Publication of JP2002531123A publication Critical patent/JP2002531123A/ja
Application granted granted Critical
Publication of JP3579355B2 publication Critical patent/JP3579355B2/ja
Publication of JP2002531123A5 publication Critical patent/JP2002531123A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000586893A 1998-12-09 1999-12-08 ヒトの乾癬を予防及び治療するための乾癬モデル動物 Expired - Fee Related JP3579355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11164298P 1998-12-09 1998-12-09
US60/111,642 1998-12-09
PCT/US1999/029123 WO2000034459A1 (en) 1998-12-09 1999-12-08 Animal model for psoriasis for the prevention and treatment of psoriasis in humans

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004145466A Division JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Publications (3)

Publication Number Publication Date
JP2002531123A JP2002531123A (ja) 2002-09-24
JP3579355B2 JP3579355B2 (ja) 2004-10-20
JP2002531123A5 true JP2002531123A5 (https=) 2005-04-07

Family

ID=22339643

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000586893A Expired - Fee Related JP3579355B2 (ja) 1998-12-09 1999-12-08 ヒトの乾癬を予防及び治療するための乾癬モデル動物
JP2004145466A Expired - Fee Related JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004145466A Expired - Fee Related JP4671265B2 (ja) 1998-12-09 2004-05-14 乾癬の治療のための医薬組成物

Country Status (10)

Country Link
US (5) US6410824B1 (https=)
EP (2) EP1336654A1 (https=)
JP (2) JP3579355B2 (https=)
AT (1) ATE305506T1 (https=)
AU (1) AU1843200A (https=)
CA (1) CA2353520C (https=)
DE (1) DE69927520T2 (https=)
DK (1) DK1137766T3 (https=)
ES (1) ES2251248T3 (https=)
WO (1) WO2000034459A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
ATE363290T1 (de) * 1999-10-04 2007-06-15 Novartis Vaccines & Diagnostic Cd40 antagonist zur behandlung von psoriasis
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003285874A1 (en) * 2002-10-16 2004-05-04 Amgen Inc. HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS
US20040260068A1 (en) * 2004-02-26 2004-12-23 Naoya Tsurushita Humanized chicken antibodies
US20060171890A1 (en) * 2005-01-28 2006-08-03 Yeomans David C Methods for evaluating the activity of candidate agents
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
CN104524567A (zh) * 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
CA2681752A1 (en) * 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
US20110002918A1 (en) * 2009-03-06 2011-01-06 Photomedex Methods of treating diseased tissue
ES2352929B1 (es) 2009-08-14 2012-01-26 Centro De Investigaciones Energeticas. Medioamb Ientales Y Tecnologicas (Ciemat) Modelo humanizado de psoriasis
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
WO2012094623A2 (en) * 2011-01-07 2012-07-12 Abbott Laboratories Anti-il-12/il-23 antibodies and uses thereof
AU2017241776B2 (en) 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
WO2018008902A1 (ko) * 2016-07-05 2018-01-11 성균관대학교산학협력단 건선 유발 동물 모델 및 이의 용도
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
BR112021005467A2 (pt) 2018-09-24 2021-06-22 Janssen Biotech, Inc. método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2191870A (en) * 1937-08-14 1940-02-27 Wayne Pump Co Liquid dispensing apparatus
US2224256A (en) * 1938-08-05 1940-12-10 Baker Chem Co J T Pharmaceutical preparation
US2297692A (en) * 1939-08-15 1942-10-06 Bendix Aviat Corp Fluid flywheel control
US2275692A (en) * 1940-04-02 1942-03-10 Sims Edward Airplane aileron
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
NL8700927A (nl) 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
IT1231727B (it) 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
US5632988A (en) * 1989-10-23 1997-05-27 Schering Corporation Polypeptide inhibitors of gamma interferon
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
WO1992006115A1 (en) * 1990-09-27 1992-04-16 Schering Corporation Antagonists of human gamma interferon
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
JP3887011B2 (ja) 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド ＩＦＮ−γインヒビターによる炎症性腸疾患の処置
US20030059428A1 (en) * 1993-02-26 2003-03-27 Boris Skurkovich Treatment of autoimmune diseases
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) * 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
JPH08289699A (ja) * 1995-04-24 1996-11-05 Chemo Sero Therapeut Res Inst 自己免疫疾患モデル動物及びその作製方法
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US20020025316A1 (en) * 1995-08-18 2002-02-28 Ferguson Mark Williams James Pharmaceutical composition containing inhibitors of interferon-gamma
GB2304342A (en) 1995-08-18 1997-03-19 Univ Manchester Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
US5945576A (en) 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
WO1997037679A1 (en) * 1996-04-10 1997-10-16 Board Of Trustees Of The University Of Illinois Interferon-gamma anti-inflammatory methods, compounds, and pharmaceutical compositions
WO1998016248A1 (en) * 1996-10-11 1998-04-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods for enhancing oral tolerance and treating autoimmune disease using inhibitors of interleukin-12
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
AU8860298A (en) * 1997-07-17 1999-02-10 F. Hoffmann-La Roche Ag Dihomo-seco-cholestanes with two unsaturated bones in the side chain
AU9262598A (en) 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
WO1999037682A2 (en) * 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
JP2002531466A (ja) * 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing

Similar Documents

Publication Publication Date Title
JP2002531123A5 (https=)
MD1374F2 (en) Monoclonal immunostimulating antibodies, method of obtaining thereof, cell lines, method of disease treatment and pharmaceutical composition
EP0200412B1 (en) Method of conferring immunotolerance to a specific antigen
Baumgarth et al. In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue
US6844011B1 (en) Methods for inhibiting rejection of transplanted tissue
Kozlowski et al. ANTI-Galα1-3Gal ANTIBODY RESPONSE TO PORCINE BONE MARROW IN UNMODIFIED BABOONS AND BABOONS CONDITIONED FOR TOLERANCE INDUCTION1
JPS61161221A (ja) Ｌｅｕ３表現型Ｔ細胞媒介性自己免疫病の治療用組成物
EP0387095A1 (en) Pharmaceutical product for the treatment of immunoregulatory disorders
JP2004506598A5 (https=)
ZA200309435B (en) Re-activated T-cells for adoptive immunotherepay
JPH0380076A (ja) 末梢血液リンパ球細胞増殖刺激法
JP2763197B2 (ja) トレランスを誘導するためのモノクローナル抗体
JP2562141B2 (ja) モノクロナ−ル抗体
US4904481A (en) Method of conferring immuno-tolerance to a specific antigen
US20070166307A1 (en) Suppression of transplant rejection
JPH10505325A (ja) 治療剤としてのｔ細胞に対する抗体
CN1651071A (zh) 治疗性蛋白抑制剂综合症的cd154阻断治疗
Howie et al. Immune response (Ir) genes expressed at macrophage–B lymphocyte interactions
EP0525570A2 (en) Anti-idiotypic antibodies that mimic TNF
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
Li et al. Polyclonal B cell activation of IgG2a and IgG2b production by infection of mice with lactate dehydrogenase-elevating virus is partly dependent on CD4+ lymphocytes
EP0282343A2 (en) Method to stimulate the immune response to specific antigens
Demetris et al. The role of passenger leukocytes in rejection and “tolerance” after solid organ transplantation: a potential explanation of a paradox
AU1454899A (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
Lance et al. Immunosuppressive effects of heterologous antilymphocyte serum in monkeys